Tiziana Life Sciences (TLSA) was up today over 17% today on almost 20x higher than average volume. So what drove the price increase? We believe it was due to initiation of analyst coverage at Zacks with a $7.50 price target. This follows a B. Riley analyst initiation at $8.00 in December. No new news or data was released by the company that we find.
What's our take on TLSA? See TLSA's drug pipeline below, from our BPIQ company page. We provide our view on TLSA in our forum article here, which you can get for free by simply signing up for a free 30-day trial to our BPIQ site (no credit and gets you a super low intro rage, that is about the cost of McDonald's happy meal). Just go to BPIQ.com and follow the links to sign up.
TLSA pipeline as of 4/12/21 from our TLSA company page on BPIQ.com.
